The recent approval of the first Hh inhibitor, glasdegib, for use in combination with low-dose cytarabine highlights the clinically relevant role of the Hh-GLI signaling pathway in treating acute myeloid leukemia (AML) patients unsuitable for high-dose chemotherapy. This evidence concerns the gene GLI1 and acute myeloid leukemia.